India, May 29 -- Dizal (688192.SS) announced the results from the phase 3 WU-KONG28 study showing that ZEGFROVY monotherapy demonstrated superior anti-tumor efficacy, compared to platinum-doublet chemotherapy, in untreated NSCLC patients with EGFR exon 20 insertion mutations.
Xiaolin Zhang, CEO of Dizal, said: "WU-KONG28 study demonstrates that ZEGFROVY can provide superior benefits for treatment naive patients. It is the first positive study for this difficult disease, providing a chemotherapy-free option for patients globally. It is the first global phase 3 study conducted by Dizal."
ZEGFROVY has previously been granted accelerated approvals in the U.S. and China for the treatment of relapsed or refractory EGFR exon 20 ins NSCLC. The ND...